A customer experienced a skin reaction while wearing an abbott diabetes care (adc) device and experienced "diffuse pimples, itching, and red scaly patches" at the sensor site.A customer had contact with a healthcare professional and was prescribed "desoximetasone ointment" twice daily for treatment.There was no report of death or permanent injury associated with this event.
|
A customer experienced a skin reaction while wearing an abbott diabetes care (adc) device and experienced "diffuse pimples, itching, and red scaly patches" at the sensor site.A customer had contact with a healthcare professional and was prescribed "desoximetasone ointment" twice daily for treatment.There was no report of death or permanent injury associated with this event.
|
Repeated attempts by adc to retrieve the product were unsuccessful and/or the customer discarded the product.The most probable root causes associated with this incident are the adhesive, including the adhesive irritating the user¿s skin, or misuse, including improper site selection and repeatedly using the same application site to place the sensor.These conditions are mitigated through the freestyle product labelling.All complaints and complaint trends are investigated to determine if there is a product defect/ deficiency.If a product defect/ deficiency is identified, a risk evaluation is completed and compared to the risk management report, to ensure the risk profile has not changed.Additionally, as a part of abbott¿s post-market surveillance process, all risk evaluations with associated complaint data are reviewed annually to determine if the risk profiles have changed as compared to the product risk management reports.These monitoring processes ensure that all product risk profiles remain acceptable and have a positive benefit/ risk ratio.At this time product has not yet been returned and a valid serial number has not been provided.An extended investigation has been performed for the reported complaint and there was no indication that the product did not meet specification.Dose audit reports were reviewed and demonstrates the continued effectiveness of the established sterilization process for libre sensor products.Environmental monitoring reports were reviewed, including bioburden and endotoxin testing, and demonstrated that all monitoring processes continue to meet adc minimum requirements for product quality.The reported complaint is related to skin irritation or an allergic reaction to the patch adhesive of the freestyle libre sensor.Clinical data was reviewed and confirmed that the freestyle libre sensors continue to be safe, effective, and perform as intended in the field.A tripped trend review was conducted for the reported complaint and libre sensor, no trends were identified that would indicate any product related issues.In the event that unanticipated product is received, a physical investigation will be performed per adc's established processes and procedures and a follow-up report will be submitted upon completion of investigation.All pertinent information available to abbott diabetes care has been submitted.
|